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Abstract 
The objective of the present investigation was to enhance the oral bioavailability 
of practically insoluble Candesartan cilexetil [CC] by preparing nanosuspension. 
The nanosuspension was prepared by media milling using zirconium oxide 
beads and converted to solid state by spray drying. The spray dried 
nanosuspension of CC [SDCN] was evaluated for particle size, zeta potential, 
saturation solubility, crystallanity, surface morphology and dissolution behavior. 
SDCN showed particle size of 223.5±5.4 nm and zeta potential of −32.2±0.6 mV 
while saturation solubility of bulk CC and SDCN were 125±6.9 μg/ml and 
2805±29.5  μg/ml respectively, showing more than 20 times increase in 
solubility. Differential Scanning Calorimetry [DSC] and X-ray diffraction [XRD] 
analysis showed that crystalline state of CC remained unchanged in SDCN. 
Dissolution studies in phosphate buffer pH 6.5 containing 0.7% Tween 20 
showed that 53±5% of bulk drug dissolved in 15 min whereas SDCN was 
almost completely dissolved exhibiting higher dissolution velocity and solubility. 
Transmission electron microscopy [TEM] revealed that nanocrystals were not of 
uniform size, and approximately of oval shape. Pharmacodynamic study based 
on deoxycorticosterone acetate [DOCA] salt model was performed in rats to 
evaluate in-vivo performance, which showed 26.75±0.33% decrease in systolic 
blood pressure for nanosuspension while plain drug suspension showed 
16.0±0.38% reduction, indicating that increase in dissolution velocity and 636  C. Detroja, S. Chavhan, and K. Sawant:   
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saturation solubility leads to enhancement of bioavailability of SDCN when 
compared to bulk CC suspension. Thus, the results conclusively demonstrated 
a significant enhancement in antihypertensive activity of candesartan when 
formulated as nanosuspension. 
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Introduction 
Candesartan, (±)1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)-
biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate,  a nonpeptide, is a selective AT1 
subtype angiotensin II receptor antagonist indicated for the treatment of hypertension 
alone or in combination with other antihypertensive agents  [1, 2]. Candesartan cilexetil 
[CC], Fig.1, is a prodrug that is hydrolyzed to candesartan during absorption from the 
gastrointestinal tract. CC has log P value of 6.1 and the aqueous solubility of CC is less 
than 5x10
−5 g/L which may be the reason for very low bioavailability i.e. about 15% [3, 4]. 
Solubility of poorly soluble compounds can be increased by formulating as aqueous pH-
shifted solutions, provided the molecules are ionizable, in mixtures of water and organic 
co-solvents, or by solubilization in Cyclodextrins [5, 6] or using emulsions [7, 8]. With the 
exception of the pH-shifted aqueous solutions, significant amounts of additives are often 
needed to increase the solubility into the millimolar range, which may induce unwanted 
side effects [9]. It would be more desirable to have a universal formulation approach to 
process any poorly soluble drug. A classical formulation approach for such poorly soluble 
drugs is micronization, where a coarse drug powder is milled to an ultrafine powder with a 
mean particle size being typically in the range of 1–10 μm. The principle is to increase the 
dissolution velocity by enlarging the surface area of the drug powder [10]. However, many 
of the new drugs exhibit so low solubility, that even micronization does not help to improve 
their bioavailability. Similarly, micronization of CC did not lead to significant enhancement 
in dissolution rate [11]. Thus, there is urgent need to have some innovative formulation 
approach to enhance the bioavailability.  
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Fig. 1.  Chemical Structure of Candesartan Cilexetil 
Nanosuspension [NS] is the best alternative and universal approach for poorly soluble 
drugs, especially which are insoluble in aqueous as well as organic media simultaneously, 
to enhance bioavailability [12–14]. Advances in technology and better understanding of the 
NS systems have attracted attention of formulation development scientists towards 
preparation of such systems. NS is sub-micron colloidal dispersion of drug particles which   Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: …  637 
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are stabilized by surfactant. It has two outstanding features: it is able to increase saturation 
solubility and consequently also increases the dissolution velocity [15, 16]. 
In general, NS can be produced by three techniques,  top-down, bottom-up and 
combination of both. Media milling and high pressure homogenization are two basic 
approaches of top-down technique. In milling approach, drug powder is dispersed in a 
surfactant solution and the obtained suspension is poured in the  milling container 
containing milling beads made from glass, stainless steel, zirconium oxide, or highly cross-
linked polystyrene resins. Then drug is nanosized by moving the beads, either by using a 
stirrer or by moving the mill container itself [17]. The Media milling techniques is very easy 
and simple method to prepare NS. 
Although the bottom-up approaches hold tremendous potential with respect to improving 
bioavailability by obtaining smaller particle sizes [<100 nm] and amorphous drug particles, 
no commercial application of these systems has yet been realized. Recently, it was 
reported that amorphous NSs are prone to Ostwald ripening; a process that leads to the 
growth of particles as time progresses. However, by incorporating a second component of 
extremely low aqueous solubility [inhibitors], Ostwald ripening can be inhibited. But, to 
inhibit ripening, the drug/inhibitor mixture [in the particles] must form a single phase; that 
is, the drug must be soluble in the inhibitor. However, when phase separation between the 
drug and inhibitor occurs, Ostwald ripening cannot be prevented [18]. Also, preparation of 
stable amorphous NS is tough and long term stabilization of amorphous drug particles is 
not easy. Hence, the easier and more viable top-down approaches are being preferred for 
the production of NS.  
Currently, nine NS based formulation are available in the US market and all are FDA 
approved from the year 2000 on. All these products are based on top-down approaches, 
eight relying on media milling and one  on high-pressure homogenization. This itself 
explains the popularity of the top-down approach and also emphasizes the ease of 
industrial scale up of this technology. A third remarkable point is that all commercial 
products are intended for oral delivery [19, 20].  
Benefits of these systems are proved by number of products in market based on these 
techniques. Hence, the aim of present investigation was to prepare NS of CC for the 
enhancement of oral bioavailability. The drug [CC] was nanosized by media milling 
technique, characterized, and evaluated for improvement in bioavailability by pharmaco-
dynamic study by measuring the blood pressure lowering effects in deoxycorticosterone 
acetate [DOCA] salt model induced hypertensive rats. 
Material and Methods 
Materials 
Candesartan cilexetil [CC] was obtained as gift sample from Alembic Research Centre, 
Baroda, India. Zirconium oxide beads were kindly provided by SPARC, Baroda, India. 
Poloxamer 407[Pluronic F 127] was purchased from BASF, Germany. Polyvinlylpyrollidone 
[PVP K-30], methanol and Tween 20 [polyoxyethylene sorbitol laureate] were purchased 
from S.D. Fine Chemicals, India. Water was filtered through Millipore 0.22μm filter before 
used. 638  C. Detroja, S. Chavhan, and K. Sawant:   
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Preparation of candesartan cilexetil Nanosuspension  
NS was prepared by media milling technique using zirconium oxide beads as milling media 
[diameter ranging from 0.4 mm to 0.7 mm] [21]. In 20 ml glass vial, 6 g of zirconium oxide 
beads and 5 ml water were added. Then 50 mg Poloxamer 407 and 25 mg drug were 
incorporated and comminution was carried out on magnetic stirrer [Remi Equipment Pvt 
Ltd, India] at 500rpm for 14 hrs [9]. Then, Mannitol at a concentration of 5%w/v of total 
formulation was dissolved in the resultant NS. This suspension was spray dried to get 
dried powder using LU-227 Advanced Spray Dryer [Lab Ultima, Mumbai, India]. Operation 
parameters in spray dryer were: inlet temperature: 115°C, outlet temperature: 55°C, 
aspiration: 1200 rpm and feed pump: 3rpm [22]. Plain drug suspension was prepared by 
dispersing the micronized powder and Poloxamer in water to get suspension with 
respective concentration of drug and surfactant as that of nanosuspension. 
Characterization of Nanosuspension  
Particle size  
Mean particle size and size distribution [polydispersity index] of the prepared NS was 
determined by using Malvern Zetasizer [NanoSeries Nano-ZS, Malvern Instruments, UK] 
which follows principle of light diffraction, also called Photon correlation spectroscopy 
[PCS]. Prior to the measurement, the samples were appropriately diluted with water to a 
suitable scattering intensity and re-dispersed by shaking before measurement. 
Zeta potential  
The Zeta potential is a measure of the electric charge at the surface of the particles, 
indicating the physical stability of colloidal systems. The zeta potential values higher than 
|30mV| indicate long-term electrostatic stability of aqueous dispersions [16]. In this study, 
the Zeta Potential was assessed by determining the electrophoretic mobility of the 
particles using Malvern Zetasizer [NanoSeries, Nano-ZS, Malvern Instruments, UK].  
Saturation solubility 
Saturation solubility is defined as being a compound-specific constant depending only on 
the temperature and polymorphic state. However, apart from these, saturation solubility is 
also a function of the particle size. This size-dependency comes only into effect for 
particles having a size below approximately 1 μm [16]. For determination of saturation 
solubility,  prepared nanosuspension was filled in a vial and kept for 24 hrs stirring to 
ensure saturation. Then 1.5 ml of NS was filled in 2 ml centrifugation tube and centrifuged 
at 25000 rpm for 30 minutes[3K 30 Sigma laboratory centrifuge, Osterode, GmBH]. 
Supernatant was filtered through 0.2 μm filter paper and analyzed spectrophotometrically 
using UV-visible spectrophotometer [UV-1700, Shimadzu AS, Japan] at 259 nm  after 
suitable dilution with phosphate buffer [pH 6.5] containing 0.7% Tween 20, which was 
used as blank. For determination of saturation solubility of bulk drug, excess quantity of 
bulk CC was added to 1.5 ml of water and then saturation solubility was also measured in 
the same way. 
X-ray Diffraction [XRD] 
XRD studies were performed to study effect of milling and spray drying on the crystallinity 
of CC. The XRD studies of bulk CC powder, Poloxamer 407, mannitol and SDCN were   Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: …  639 
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carried out using X-ray diffractometer [XRD] [Brucker AXS, model D8 advanced, Germany] 
with Cu line as source of radiation at Electrical Research and Development Agency, 
Baroda, Gujarat, India. Standard runs were taken using 40kV voltage, 40mA current and 
scanning rate of 0.02°/min over a 2θ range of 5–50°. 
Differential Scanning Calorimetry [DSC] 
DSC studies were performed to investigate the effect of surfactants, milling process and 
drying process on the inner structure of candesartan cilexetil and to confirm crystallinity 
result obtained by XRD. The DSC thermograms of bulk CC powder, Poloxamer 407, their 
physical mixture and SDCN were taken on a DSC-60 Shimadzu [Shimadzu AS, Japan] 
Differential Scanning Calorimeter between 40–300 °C at a heating rate of 10 °C/min with 
nitrogen supplied at 40 ml/min.  
Transmission Electron Microscopy [TEM]  
Morphological evaluation of NS was conducted by Transmission Electron Microscopy. 
TEM images were recorded using Transmission Electron Microscope [Philips Technai-20]. 
The liquid NS formulation was dropped on copper-gold carbon coated grid and allowed to 
dry. This grid was then mounted in the instrument and photographs were taken at various 
magnifications.  
Dissolution studies 
Dissolution experiments were performed using USP 24 paddle instrument [Electrolab 
TDT-06P]. The dissolution medium was used in this study i.e. phosphate buffer [pH 6.5] 
containing 0.7% Tween 20  [23].  The medium (250 ml) was gently transferred into the 
dissolution vessel so as to minimize foaming of the medium during the experiment. 
Dissolution was performed at 37°C, using a paddle speed of 100 rpm. Samples of bulk CC 
and SDCN equivalent to 15 mg of CC were added to dissolution vessels and aliquots were 
withdrawn at suitable time intervals for 60 min, and filtered immediately through 0.1μm 
PTFE syringe filter [Whatman Inc., Clifton, NJ, USA] [21]. Subsequently, same volume of 
fresh medium was added to the dissolution vessel. Quantification of the samples was done 
by UV analysis at 259nm. The experiment was performed three times. 
Stability studies 
Stability studies of the NS and SDCN were conducted at two different storage conditions 
[Room temperature (RT) and Refrigerated (RF i.e. 2–8 °C)] for 2 months. Three batches 
for both formulations were used for each condition. The physical stability of nanosized 
formulations was judged in terms of particle size determined at specific time intervals. 
Assay was also carried out periodically to determine the chemical stability of CC. To 
determine the drug content, formulation with amount equivalent to 2.5 mg of CC was 
dissolved in methanol, diluted appropriately, filtered and absorbance of resulting solution 
was measured spectroscopically at 255.5 nm.  
In vivo studies  
A pharmacodynamic method was applied to determine enhancement in bioavailability due 
to NS of CC as compared to plain drug suspension. Candesartan inhibits the pressor 
effects of angiotensin II infusion in a dose-dependent manner [24,25]. Hence, decrease in 
pressor effect can be directly correlated with the amount of drug that reaches the systemic 640  C. Detroja, S. Chavhan, and K. Sawant:   
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circulation i.e. to the bioavailability of the drug. In other words, greater the inhibition of the 
pressor effect, higher the bioavailability of the administered formulation. The 
pharmacodynamic study was thus based on this hypothesis. 
DOCA [deoxycorticosterone acetate] salt model was applied to induce hypertension in rats 
[26]. After induction of hypertension, treatment was started with plain drug suspension and 
NS and blood pressure was measured by tail-cuff method using LE 5002 Storage 
Pressure Meter [Letica Scientific Instruments]. The animal experiments are conducted in 
full compliance with Institutional Animal Ethical Committee [IAEC] regulations, as per 
CPCSEA guidelines. The registration number of our institute is 404/01/a/CPCSEA.  
DOCA salt hypertensive rats 
Female Wistar rats [weight approximately 200–250 g] obtained from Zydus Research 
Centre, Ahmadabad, India were used for the study. These animals were divided into six 
groups, each containing four rats. All rats were uninephrectomised under anesthesia with 
intraperitoneal ketamine [100 mg/kg]. Kidneys were visualized by a right lateral abdominal 
incision. The right kidney was removed after ligation of adjoining renal vasculature and 
ureter with sutures i.e. uninephrectomy. After one week recovery period, 
uninephrectomized rats were given either no further treatment [UNX rats] or 1% NaCl in 
drinking water with subcutaneous injections of deoxycorticosterone acetate [DOCA; 25mg 
in corn oil every fourth day] [DOCA-salt rats]  [25]. DOCA-salt rats were further sub-
grouped into five according to treatment given to them: D1 & D2-low dose nanosuspension 
and plain drug suspension, respectively [0.5mg/kg/day], D3 & D4-high dose nano-
suspension and plain drug suspension, respectively [5mg/kg/day], D0-no treatment [DOCA 
control] [27]. To get bulk drug suspension, plain CC with equivalent quantity of surfactant 
of NS was suspended into distilled water before administration, while nanosuspension was 
administered as such after suitable dilution. After 14 days, all subgroups of DOCA-salt rats 
except D0 subgroup were orally administered candesartan cilexetil formulations daily for 
further 7 days. 
Measurement of systolic blood pressure 
Systolic blood pressure was measured once a week before drug administration for first two 
weeks [using tail-cuff method]. During treatment, systolic blood pressure was measured 
daily for all subgroups of DOCA salt rats except D0, 2–3 hours after administration. In UNX 
rats and D0 rats, blood pressure was measured once a week throughout the experiment. 
Statistical analysis 
ANOVA was applied followed by t-test to determine differences in decrease in blood 
pressure between groups; p < 0.05 was considered significant.  
Results and Discussion 
Preparation of candesartan cilexetil Nanosuspension  
Media milling technique using zirconium oxide beads was adopted as it uses least number 
of equipments and is a relatively easy method. By using factorial design the formulation 
parameters were optimized (Data not shown). The particle size of optimized batch was 
found to be 223.5±5.4, indicating the usefulness of media milling method for nanosizing.   Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: …  641 
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Effective milling was observed at bead concentration of 120% w/v and no further 
improvement was observed when concentration of beads was increased beyond this limit. 
Plain drug suspension particle size was determined by Malvern 2000 Mastersizer and 
found to be 54± 8.0 μm. 
Stabilization of the nanoparticles in a NS form requires a stabilizer that binds onto the 
particle surface [28, 29]. Poloxamer adsorb strongly onto the surface of hydrophobic 
nanoparticles via their hydrophobic polyoxypropylene centre block and have been shown 
to be quite successful in regard to stabilization of nanoparticles  [30]. Two stabilizers, 
Poloxamer 407 and PVP K-30 were tried to stabilize the formulation. The average particle 
size obtained using Poloxamer 407 was 223.5±5.4 nm while with PVP K-30, it was 236.0 ± 
14.0 nm. The PDI values were also less for Poloxamer 407. Based on these results, 
Poloxamer 407 was found to be a better stabilizer of the NS of CC.  
To incorporate nanocrystals into solid dosage forms [e.g. tablets, capsules, pellets etc.], 
the transformation of the liquid aqueous nanocrystals into a dry nanocrystals powder is 
necessary. Technically, it can be achieved using established unit operations such as 
freeze-drying, spray-drying, pelletization or granulation  [31]. But, choice of the drying 
technology is important, because it needs to be ensured that the nanocrystals can be re-
dispersed as separated particles and do not aggregate, which would lead to a loss of their 
special properties. Spray drying is a commonly used method to transform a crystalline 
drug substance into its high energy, thermodynamically metastable, amorphous state. It is 
simple, widely used and effective for nanosizing the drug.  
In the present investigation, spray drying was performed to dry the aqueous NS of CC. In 
spray drying, a matrix former like sugar is often added to the suspension prior to the drying 
operation to preserve particle size of nanocrystals. Typical matrix formers added prior to 
drying are water soluble sugars like mannitol, dextrose, sucrose. In this study, mannitol at 
a concentration of 5%w/v of total formulation was added. SDCN was further investigated 
with respect to redispersability and particle size. SDCN could be easily and completely 
redispersed upon the addition of water without aggregates or agglomerates. 
Characterization of Nanosuspension  
Particle size analysis  
The particle size [PCS] of the NS was determined before and after spray drying to study 
the effect of spray drying on particle size. PCS before spray drying was 223.5±5.4 nm with 
a polydispersity index [PI] of 0.234±0.021 while after re-dispersion of SDCN, the PCS and 
PI were 229.6±4.0 nm and 0.237±0.018, respectively. This data reveals that converting the 
NS into the dry powder using spray drying had no adverse influence on the particle size, 
polydispersity index and redispersability of CC nanocrystals.  
Zeta potential 
Colloidal systems must preserve their characteristics like particle size and colloidal stability 
to get advantage of these systems. Technically, colloidal stability is measured in the form 
of zeta potential. Generally, zeta potential value of ±30 mV is the minimum for a physically 
stable NS solely stabilized by electrostatic repulsion and the corresponding value is about 
±20 mV in the case of a combined electrostatic and steric stabilization [16]. Zeta potential 642  C. Detroja, S. Chavhan, and K. Sawant:   
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of NS and SDCN was found to be -33.2±0.86 mV and -32.2±0.59 mV. Thus, it was 
concluded that the systems had sufficient stability. 
Saturation solubility 
Saturation solubility will increase if the particle size of the nanocrystals is reduced below 
particular limit. Thus, nanonization might leads to increase in the saturation solubility. 
Buckton and Beezer assumed that the enhancement of solubility is valid only for sparingly 
soluble particles of less than 1 µm in size [32]. The average particle size of re-dispersed 
CC nanocrystals was below 1 µm, thus, theoretically it will help in improving saturation 
solubility and thus bioavailability. Saturation solubility was determined in the official 
dissolution medium for CC. Saturation solubility of SDCN and bulk CC at room 
temperature in phosphate buffer [pH 6.5] containing 0.7% Tween 20 was 2805±29.5 
μg/mL and 125±6.9 μg/mL respectively. Thus, saturation solubility of SDCN was 22.44 
times that of bulk drug. This greater than 200% increase in solubility of CC due to particle 
size reduction can be expected to enhance dissolution velocity and bioavailability, 
justifying the objective of this work. There was no significant difference in saturation 
solubility of drug before and after spray drying i.e. after addition of mannitol. Also in case 
of physical mixture (CC and poloxamer) no significant difference in saturation solubility 
was observed. 
X-ray Diffraction pattern [XRD] 
XRD pattern of bulk CC, SDCN, Poloxamer 407 and mannitol are shown in Fig. 2. The 
major peaks of the CC are present in SDCN and the additional peaks appeared in SDCN 
are may be due to mannitol. These results showed that crystalline state of the bulk drug 
and SDCN was same indicating milling and drying processes did not induce a crystalline 
or polymorphic transition of the drug. Likewise, stabilizers did not influence the crystallinity 
of the candesartan cilexetil nanocrystals. In general, crystalline substances are physically 
more stable compared to amorphous forms. Therefore, it can be assumed that the spray 
dried nanocrystals will be physico-chemically stable during the storage. It can also be 
safely assumed that, better physicochemical properties such as observed; enhanced 
solubility and dissolution velocity can be attributed to the particle size reduction and not to 
alterations in crystalline state. 
Differential Scanning Calorimetry [DSC] 
The DSC studies were performed to study the effect of nanosizing and spraying drying on 
solid state of CC. The DSC thermograms of CC bulk powder, SDCN, physical mixture and 
Poloxamer 407 are shown in Fig. 3. The DSC thermogram of bulk CC powder showed a 
sharp endothermic peak at 168°C followed by an exothermal peak at which is due to 
decomposition of the drug [33].The thermogram of Poloxamer showed endothermic peak 
at 55°C. Both, Physical mixture and the formulation showed sharp endothermic peaks at 
168°C which drug remained in crystalline state. We can also conclude that the melting 
curve of CC was not influenced by either stabilizer or milling and drying process. Thus, the 
combined results from XRD and DSC studies show that nanosizing and spray drying does 
not affect the crystallinity of candesartan cilexetil.  
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Fig. 2.   X-ray Diffraction pattern of bulk drug, formulation, Poloxamer 407 and Mannitol 
 
 
 
Fig. 3.   DSC thermogram of Candesartan cilexetil bulk powder, Poloxamer 407, 
physical mixture and spray dried nanosuspension(SDCN).  644  C. Detroja, S. Chavhan, and K. Sawant:   
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Transmission Electron Microscopy [TEM]  
The morphological characteristics of the NS was determined using TEM [Fig. 4]. It was 
observed that the nanocrystals were not of uniform size and approximately of oval shape 
and the non-uniformity of the nanocrystals could be attributed to method used for 
nanosizing. It can also be seen that the drug particles were non-aggregated and uniformly 
dispersed in the medium. This was also reflected by comparative high polydispersivity 
index [PDI] of 0.234± 0.21. 
 
Fig. 4.   TEM photograph of Nanosuspension (Bar line= 500nm). 
Dissolution study 
The most important feature of nanocrystals is the increase in the dissolution velocity, not 
only because of increase in surface area but also because of increase in saturation 
solubility. This phenomenon is best explained by Noyes-Whitney law [Eq. 1].  
Eq. 1.  
dm
dt =
DA
h [CS − CX] 
Where, dm/dt= dissolution velocity, D = diffusion coefficient, A = surface area, Cs  = 
saturation solubility, Cx = bulk concentration, and h = diffusional distance over which the 
concentration gradient occurs. Division of the equation by the volume v leads to dc/dt. It is 
obvious that an  increase in A increases the dissolution velocity.  According to Noyes-
Whitney, the increase in Cs  in addition to A further increases the dissolution velocity. 
According to the Prandtl equation [Eq. 2], the diffusional distance h decreases for very 
small particles. 
Eq. 2.   hH=k�L
1
2 �  − V
2
3 � � 
Where hH= hydrodynamic boundary layer thickness; k= constant; L= length of surface in 
direction of flow, V= Relative velocity of flowing liquid against flat surface   Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: …  645 
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Fig. 5.   Dissolution rate of plain drug and spray dried nanosuspension of Candesartan 
cilexetil. 
When the dissolution profile of the SDCN was compared with bulk CC, improved 
dissolution was observed. In SDCN, 76.3%±3.4 of the drug got dissolved within 4 minutes 
and about 99.4±3.6% within 15 minute, while bulk CC showed only 17.0±2.0% release at 
the end of 5 minutes and 53.5±5.0% release in 15 minutes. Thus, there was improvement 
in dissolution rate for SDCN compared to plain drug [Fig. 5]. The particle size reduction 
from 54± 8.0 μm to 223.5±5.4 is responsible for this improvement as the excipient in both 
case are same. This dissolution rate of the spray dried nanocrystals was distinctly superior 
compared to plain drug, which might be attributed to increase in surface area, saturation 
solubility and decrease in diffusional distance for nanocrystals, showing complete 
dissolution within minutes. 
Stability studies  
Physical stability 
Particle size of NS formulation was measured after 15, 30, and 60 days. The results are 
shown Fig. 6. Particle size of NS increased from 223.5±5.4 nm to 375.3±6.0 nm in 60days 
at room temperature, while at refrigerator condition it increased from 225.9±2.7 to 
300.6±3.6 nm. For spray dried nanosuspension, particle size increased from 229.6±4.0 nm 
to 269.3±2.7 nm in 60days at room temperature (RT), while at refrigerator condition (RF) it 
increased from 226.9±4.1 to 251.1±3.6 nm. The crystal growth could be explained by 
Ostwald ripening. Generally, Ostwald ripening is a result of the difference in solubility 
between small and large particles due to a higher degree of curvature of small particles 
leading to higher solubility compared with the larger ones [34]. Thus, the SDCN showed 
lesser increase in particle size under both conditions compared to NS before spray drying. 
Thus, it is recommended  to store the spray dried nanosuspension under refrigerator 
condition to minimize increase in particle size during storage. 
 646  C. Detroja, S. Chavhan, and K. Sawant:   
Sci Pharm. 2011; 79: 635–651 
 
Fig. 6.   Change in particle size of nanosuspension and spray dried nanosuspension at 
various conditions. 
Chemical stability 
Assay results of CC in the NS and SDCN after 15, 30 and 60 days stored at room temper-
ature (RT) and refrigeration conditions (RF) were shown in Table 1. The amount of CC 
remaining in the formulation was mainly dependent on type of surfactant and the storage 
condition. The percentage of active measured in case of NS was higher than SDCN.  
Tab. 1.   Assay of optimized batches of nanosuspension at various conditions 
Stability 
condition  Formulation  %Assay (±S.D.) 
Initial  15days  30days  60days 
Room 
temperature 
Nanosuspension  99.73±0.36  99.01±0.36  98.25±0.65  97.96±0.25 
Spray-dried 
Nanosuspension  98.75±0.35  98.05±0.36  97.59±0.85  96.98±0.25 
Refrigerator 
Nanosuspension  99.79±0.91  99.25±0.12  98.75±0.15  98.02±0.12 
Spray-dried 
Nanosuspension  98.69±0.61  98.14±0.16  97.75±0.35  97.18±0.14 
 
The chemical stability observed was satisfactory at both conditions for 2 months as active 
content was more than 95% in all cases. Although the active contents are above 95%, it 
follows a downward trend with time so its storage should be maintained at refrigerated 
condition. Thus, it can be concluded that the chemical stability of CC was not affected due 
to milling and the formulation was stable for 2 months. Further studies are needed to prove 
long term stability of the formulation and to find out reasons for the downward trend. 
However, similar results are reported in some cases [35]. 
In vivo study  
As shown in Table 2, systolic blood pressure of UNX rats after 4 weeks was 135.0±5.2 
mmHg compared to DOCA-salt rats 165.0±4.6 mmHg, i.e. only uninephrectomy was not   Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: …  647 
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sufficient to develop significant rise in systolic blood pressure. All DOCA-salt rats showed 
mild but significant hypertension in two weeks. Table 2 shows % decrease in systolic blood 
pressure of rats after one week of treatment.  
Tab. 2.   Mean systolic blood pressure in different groups of rats 
Group  Systolic blood pressure(mmHg) 
% Decrease in 
systolic blood 
pressure after 
treatment** 
0 d  7 d  14 d  17 d  21 d   
UNX rats  107±3.2  119±2.5  124±2.5  –  135±5.2  – 
DOCA 
rats 
D0  110±4.6  126±2.9  153±6.1  –  165±4.6  – 
D1  105±6.2  121±1.9  156±3.1  139±5.2  128±2.4  17.94±0.357
a 
D2  109±3.9  124±3.8  152±5.9  142±3.2  138±3.2  12.89±0.425 
D3  115±5.4  129±5.2  157±5.9  127±5.2  115±2.1  26.75±0.335
a 
D4  114±3.5  128±2.5  150±6.1  136±4.3  126±2.6  16.0±0.379 
** %decrease in systolic blood pressure after one week of treatment in comparison to that of after 
14 days (Actual measurements were done daily in all treatment groups but here for comparison 
one week time point was used); Each value represents the mean ± S.E.M. (n=4); 
aP < 0.05, 
compared with rats receiving plain drug suspension; D0: DOCA control (no treatment); D1: rats 
receiving low dose nanosuspension; D2: rats receiving low dose plain drug suspension; D3: rats 
receiving high dose nanosuspension; D4: rats receiving low dose plain drug suspension. 
 
After one week treatment, D1 rats [receiving low dose nanosuspension] showed 
17.94±0.36% and D2 rats [receiving low dose plain drug suspension] showed 
12.89±0.42% decrease in systolic blood pressure. Similarly, D3 rats [receiving high dose 
nanosuspension] showed 26.75±0.34% and D4 rats [receiving high dose plain drug 
suspension] showed 16.0±0.38% decrease in systolic blood pressure. This significant 
enhancement in antihypertensive activity was clearly observed in Fig. 7 and attributed to 
nanosizing of candesartan cilexetil.  
Thus, it was confirmed that Candesartan cilexetil decreases blood pressure in a dose-
dependent manner and hence decrease in pressor effect can be directly correlated with 
the amount of drug that reaches systemic circulation i.e. bioavailability of drug. In other 
words, higher the inhibition of pressor effect, more the bioavailability of CC from 
administered formulation. The data also clearly demonstrated that inhibition of pressor 
effect was greater in rats receiving NS in comparison to rats receiving plain drug 
suspension at both doses. Based on this pharmacodynamic study, it could be concluded 
that bioavailability of CC was higher from NS in comparison to plain drug suspension, 
although it was difficult to quantify actual increase in bioavailability from this pharmaco-
dynamic study.  
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Fig. 7.   % Decrease in systolic blood pressure after treatment in different groups. 
(*…Indicates significant difference between two groups) 
Conclusion 
Formulation strategy of using nanocrystalline drug was investigated as a way to improve 
bioavailability of the Candesartan cilexetil. Media milling method using zirconium oxide 
beads was effective in nanosizing the drug and the spray dried nanosuspension showed 
improved stability compared to nanosuspension. XRD pattern and DSC results revealed 
the unchanged crystalline nature of CC in the spray dried product. Saturation solubility of 
CC was increased 22.44 times than that of bulk drug by nanosuspension formulation. In 
case of spray dried nanosuspension the increased surface area, higher saturation 
solubility and reduced diffusion distance led to increased dissolution velocity. The spray 
dried formulation was stable for two months at refrigeration condition. The results of the 
pharmacodynamic study showed significant reduction in blood pressure for nano-
suspension as compare to plain drug suspension. Thus, the results of the in vitro and 
pharmacodynamic studies conclusively demonstrated significant enhancement in 
antihypertensive activity of candesartan when formulated as nanosuspension. 
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